Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). $20M drawn at closing within a potential $200M senior secured facility maturing June 1, 2031.
4D Molecular Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $20M drawn at closing within a potential $200M senior secured facility maturing June 1, 2031
- Additional $180M contingent on elections, milestones, or Hercules’ discretion, preserving funding capacity but limiting certainty
- Interest rates floor at 8.75% for Tranche 1A and 9.25% for other tranches, creating meaningful financing expense
- Substantially all assets, including intellectual property, secure the loans, increasing creditor claims on core biotechnology assets
- Financial covenants impose minimum-cash and post-approval performance requirements, with default enabling accelerated repayment
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 section contains only the filing signature and date
- No debt amount, interest rate, maturity, lender, or borrowing purpose disclosed in provided text
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 4D Molecular Therapeutics, Inc. 8-K filings
Get the next FDMT 8-K as it lands
Follow FDMT for push alerts, or ask the research agent what this filing means.